Newland Pharmaceutical Co., Ltd. (SHE:301277)
China
· Delayed Price · Currency is CNY 12.31
-0.08 (-0.65%)
Mar 9, 2026, 4:00 PM EDT
Newland Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Net Income | 123.72 | 173.63 | 158.98 | 132.3 | 114.98 | 118.46 | Upgrade
|
| Depreciation & Amortization | 37.53 | 37.53 | 31.08 | 24.24 | 20.86 | 17.95 | Upgrade
|
| Other Amortization | 2.54 | 2.54 | 1.54 | 0.16 | - | - | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | -0.07 | 0.44 | 0.21 | 0.12 | Upgrade
|
| Asset Writedown & Restructuring Costs | 2.62 | 2.62 | 1.46 | 0.32 | 0.11 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -13.95 | -13.95 | -17.6 | -1.52 | -0.17 | - | Upgrade
|
| Stock-Based Compensation | - | - | - | - | - | 1.47 | Upgrade
|
| Provision & Write-off of Bad Debts | 2.27 | 2.27 | -3.6 | 2.23 | 11.14 | 2.21 | Upgrade
|
| Other Operating Activities | 63.39 | 5.05 | -0.65 | 6.29 | 6.54 | 4.63 | Upgrade
|
| Change in Accounts Receivable | -82.3 | -82.3 | 117.51 | -146.8 | -99.16 | -92.31 | Upgrade
|
| Change in Inventory | -18.25 | -18.25 | 21.6 | 25.05 | -29.15 | -17.44 | Upgrade
|
| Change in Accounts Payable | 17.32 | 17.32 | -54.7 | 28.45 | 20 | 12.77 | Upgrade
|
| Change in Other Net Operating Assets | 0.3 | 0.3 | -0.48 | 5.28 | 3.9 | - | Upgrade
|
| Operating Cash Flow | 135.19 | 126.76 | 259.46 | 82.85 | 49.08 | 47.86 | Upgrade
|
| Operating Cash Flow Growth | -47.27% | -51.14% | 213.19% | 68.80% | 2.55% | 21.49% | Upgrade
|
| Capital Expenditures | -118.69 | -110.79 | -96.51 | -74.34 | -25.4 | -16.96 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.19 | 0.14 | 0.54 | 0.04 | 0.06 | 0.12 | Upgrade
|
| Investment in Securities | 222.98 | 78.28 | 129.46 | -691.5 | -8.5 | - | Upgrade
|
| Other Investing Activities | -2.17 | - | - | 0.33 | 0 | - | Upgrade
|
| Investing Cash Flow | 102.31 | -32.36 | 33.48 | -765.47 | -33.83 | -16.84 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | - | 9.6 | Upgrade
|
| Long-Term Debt Issued | - | - | - | 89.09 | 118.46 | 112.75 | Upgrade
|
| Total Debt Issued | - | - | - | 89.09 | 118.46 | 122.35 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | - | -9.6 | Upgrade
|
| Long-Term Debt Repaid | - | -3.25 | -2.75 | -203.05 | -100 | -71.45 | Upgrade
|
| Total Debt Repaid | -4.1 | -3.25 | -2.75 | -203.05 | -100 | -81.05 | Upgrade
|
| Net Debt Issued (Repaid) | -4.1 | -3.25 | -2.75 | -113.96 | 18.46 | 41.3 | Upgrade
|
| Issuance of Common Stock | - | - | - | 838.57 | 4 | 1 | Upgrade
|
| Common Dividends Paid | -112.02 | -80.02 | -66.68 | -6.77 | -36.7 | -54.46 | Upgrade
|
| Other Financing Activities | 0.25 | - | - | -19.09 | -6.94 | -1.56 | Upgrade
|
| Financing Cash Flow | -115.88 | -83.26 | -69.43 | 698.74 | -21.19 | -13.72 | Upgrade
|
| Net Cash Flow | 121.47 | 11.14 | 223.51 | 16.12 | -5.94 | 17.3 | Upgrade
|
| Free Cash Flow | 16.5 | 15.97 | 162.94 | 8.5 | 23.68 | 30.9 | Upgrade
|
| Free Cash Flow Growth | -87.79% | -90.20% | 1816.39% | -64.10% | -23.36% | 4.11% | Upgrade
|
| Free Cash Flow Margin | 2.46% | 2.20% | 25.01% | 1.35% | 4.61% | 7.13% | Upgrade
|
| Free Cash Flow Per Share | 0.04 | 0.04 | 0.42 | 0.03 | 0.08 | 0.11 | Upgrade
|
| Cash Income Tax Paid | 51.15 | 53.72 | 43.59 | 66.68 | 43.77 | 43.95 | Upgrade
|
| Levered Free Cash Flow | 26.78 | 29.72 | 158.98 | -11.33 | -12.63 | -51.2 | Upgrade
|
| Unlevered Free Cash Flow | 26.82 | 29.78 | 159.06 | -7.03 | -8.43 | -48.83 | Upgrade
|
| Change in Working Capital | -82.93 | -82.93 | 88.32 | -81.62 | -104.59 | -96.97 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.